|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
AHN-GOOK PHARMACEUTICAL CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name AHN-GOOK PHARMACEUTICAL CO.,LTD. Headquarters ANGUK PHARCEUTICAL CO., 993-75, DAERIM 2-DONG, YEONGDEUNGPO-GU, SEOUL; Seoul; Seoul; 150953 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: CHUNGJUNG (2011) Incorporation Date: February 12, 1959 Total Employees: 463 Tel: 02-3289-4200 |
|
Company Description |
| Sales increased over the year-earlier period with steady sales of main products such as digestive relaxants, respiratory relaxants, and eye preparations.Profitability decreased from the year-earlier period due to price rise of main material drugs while government regulated markup of finished products.Stable financial structure is maintained based on strong operating cash flow and low debt ratio. Sales growth will continue with stable demand for main products and launch of new products through constant | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues increased with 10.07%, from KRW 58,570,493 thousands to KRW 64,470,914 thousands. Operating result decreased from KRW 8,176,601 thousands to KRW 7,271,243 thousands which means -11.07% change. The results of the period increased 22.00% reaching KRW 6,507,054 thousands at the end of the period against KRW 5,333,629 thousands last year. Return on equity (Net income/Total equity) went from 4.63% to 5.62%, the Return On Asset (Net income / Total Asset) went from 3.50% to 3.85% and the Net Profit Margin (Net Income/Net Sales) went from 9.11% to 10.09% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 45.84% compared to 32.34% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 3.16 to 2.63 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 H1 (non-cons) |
2011 Y (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
168,978,451 |
159,659,663 |
| ||
Current Assets |
118,985,417 |
110,295,965 |
| ||
Total Liabilities |
53,109,599 |
49,025,149 |
| ||
Shareholders Equity |
115,868,852 |
110,634,514 |
| ||
Current Liabilities |
45,239,692 |
41,353,196 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
64,470,914 |
121,222,378 |
| ||
Operational Profit (Loss) |
7,271,243 |
9,088,274 |
| ||
Net Profit (Loss) |
6,507,054 |
6,605,674 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
3.85% |
4.14% |
| ||
Return on Equity (ROE) |
5.62% |
5.97% |
| ||
Return on Sales (ROS) |
10.09% |
5.45% |
| ||
Return on Capital |
5.26% |
5.58% |
| ||
Gross Profit Margin |
51.16% |
49.91% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
0.54x |
1.10x |
| ||
Asset Turnover |
0.38x |
0.76x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
4,817,295 |
2,549,208 |
| ||
EBITDA |
7,271,243 |
9,160,188 |
| ||
Bookvalue (BV) |
112,853,806 |
107,061,072 |
| Liquidity Ratios | ||
| ||
Current Ratio |
263.01% |
266.72% |
| ||
Quick ratio |
182.07% |
206.06% |
| ||
Doom's day ratio |
17.19% |
11.55% |
| ||
Cash Flow to Debt |
5.64% |
5.59% |
| Leverage Ratios | ||
| ||
Leverage ratio |
145.84% |
144.31% |
| ||
Interest Coverage Ratio |
1,784.73% |
1,210.84% |
| ||
Debt to equity |
45.84% |
44.31% |
| ||
Debt to total assets |
31.43% |
30.71% |
| ||
Long Term Debt to Capital |
6.36% |
6.48% |
| Market ratios | ||
| ||
Price/Book Ratio |
0.70 |
0.71 |
| Trend Ratios | ||
| ||
Revenue Trend |
110.07% |
112.03% |
| ||
Net Income Trend |
122% |
44.13% |
| ||
 |